<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05000554</url>
  </required_header>
  <id_info>
    <org_study_id>STARS-GC02</org_study_id>
    <nct_id>NCT05000554</nct_id>
  </id_info>
  <brief_title>The Safety and Efficacy of PD-1 Monoantrapical Chemotherapy in the Treatment of Local Advanced Stomach Cancer</brief_title>
  <official_title>The Safety and Efficacy of PD-1 Monoantrapical Chemotherapy in the Treatment of Local Advanced Stomach Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Hospital of Jilin University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Hospital of Jilin University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To explore the safety and efficacy of local advanced stomach cancer patients receiving new&#xD;
      complementary treatment of PD-1 monoantiotherapy before surgery&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 2, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2026</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pCR rate</measure>
    <time_frame>30 days</time_frame>
    <description>Defined as the complete disappearance of tumor cells under a microscope after the completion of the neoadjuvant stomach cancer treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>30 days</time_frame>
    <description>defined as the proportion of patients whose tumor volume has shrunk to a predetermined value and can maintain the minimum time limit. The sum of complete remission plus partial remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>3 years</time_frame>
    <description>Defined as the time from the start of randomization to the progression of the disease or the death of the patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>3 years</time_frame>
    <description>Defined as the time between the beginning of randomization and the death of the patient for any reason.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postoperative complication</measure>
    <time_frame>Up to 30 days post-operative</time_frame>
    <description>Defined as postoperative complications that occur within 30 days of surgery, they are classified according to the Clavien-Dindo classification system.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>operative mortality</measure>
    <time_frame>Up to 30 days post-operative</time_frame>
    <description>Defined as death of any cause within 30 days of surgery.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Locally advanced gastric cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with locally advanced gastric cancer who can receive PD-1 monoclonal antibody combined with neoadjuvant chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Neoadjuvant Therapy</intervention_name>
    <description>Drug:&#xD;
Camrelizumab 200mg,d1，Repeat every 21 days for 3 courses； Oxaliplatin 130mg/m² ,d1;S-1 40-60mg,Bid, d1-14; S-1: bsa&lt;1.25m2,40mg/time，twice a day；bsa1.25~1.5m2，50mg/time，twice a day；bsa≥1.5m2,60mg/次，twice a day，d1-d14；&#xD;
Procedure: Gastric cancer resection Distal gastrectomy combined with D2 lymph node dissection</description>
    <arm_group_label>Locally advanced gastric cancer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically proven adenocarcinoma of the stomach, PD-L1+(CPS≥1).&#xD;
&#xD;
          2. Clinical cT3-4a/N+M0 disease, confirmed by upper gastrointestinal endoscopy and&#xD;
             abdominal computed tomography (CT) and laparoscopy.&#xD;
&#xD;
          3. The gastric tumors are macroscopically resectable by distal gastrectomy with D2 lymph&#xD;
             node dissection, and R0 or R1 resection can be achieved.&#xD;
&#xD;
          4. No bulky lymph node metastasis is detected by abdominal CT.&#xD;
&#xD;
          5. No pleural effusion, no ascites exceeding the pelvis and no metastasis to the&#xD;
             peritoneum, liver or other distant organs are confirmed by abdominal pelvic CT.&#xD;
&#xD;
          6. No clinically apparent distant metastasis.&#xD;
&#xD;
          7. Karnofsky performance status ≥70%.&#xD;
&#xD;
          8. Sufficient oral intake.&#xD;
&#xD;
          9. No previous treatment with chemotherapy or radiation therapy for any tumors.&#xD;
&#xD;
         10. No previous surgery for the present disease.&#xD;
&#xD;
         11. Sufficient organ function, as evaluated by laboratory tests 7 days or more after the&#xD;
             date when the anticancer drugs were given. When patients are recovering from&#xD;
             myelosuppression,the revised criteria are shown in parentheses. White blood cell&#xD;
             count≥3000/mm3 (2000/mm3) Platelet count≥10.0*104/mm3 (5.0*104/mm3) Aspartate&#xD;
             aminotransferase≤100 IU/l Alanine aminotransferase≤100 IU/l Total bilirubin≤2.0 mg/dl&#xD;
             Serum creatinine≤1.5 mg/dl&#xD;
&#xD;
         12. No need for emergency surgery due to bleeding or perforation of the primary tumor.&#xD;
&#xD;
         13. No mechanical obstruction.&#xD;
&#xD;
         14. Written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Past history of upper abdominal surgery.&#xD;
&#xD;
          2. Past history of surgery for the gastrointestinal tract.&#xD;
&#xD;
          3. Body mass index exceeding 30 kg/m2.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Di Guo</last_name>
    <phone>0431-88782013</phone>
    <email>guodi17790060921@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>the First Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Di Guo</last_name>
      <phone>0431-88782013</phone>
      <email>guodi17790060921@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 28, 2021</study_first_submitted>
  <study_first_submitted_qc>August 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 11, 2021</study_first_posted>
  <last_update_submitted>August 3, 2021</last_update_submitted>
  <last_update_submitted_qc>August 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The First Hospital of Jilin University</investigator_affiliation>
    <investigator_full_name>Quan Wang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

